Breaks Categories: News

WednesdaySep 04, 2024 1:53 pm

NetworkNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Releases Q2 Report, AVERSA Fentanyl Update

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical products, is reporting its Q2 2024 financial results for the period ending July 31, 2024. According to the report, the company ended the quarter in a strong cash position, reinforcing its ability to advance the development of its lead product, AVERSA(TM) Fentanyl, with a New Drug Application (“NDA”) submission planned for the first half of 2025. The report showed Nutriband with cash reserves of $6.75 million, supporting the company's ongoing development and commercialization efforts for AVERSA Fentanyl; total assets are valued at $13.63 million, with stockholders' equity amounting to $12.5 million. The…

Continue Reading

WednesdaySep 04, 2024 1:37 pm

NetworkNewsBreaks – TC Biopharm (Holdings) PLC (NASDAQ: TCBP) Doses Five New Patients in UK ACHIEVE Phase 2b Trial

TC Biopharm (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, has dosed five new patients in the ongoing ACHIEVE phase 2b trial in the United Kingdom. According to the announcement, that brings the total number of patients dosed to six; five patients have received a second dose and two patients have received a third dose. The announcement noted that there are four possible doses at the higher dose level, with each 5mL dose containing up to 230 million gamma delta T cells. New patients will continue to be identified, screened and enrolled into…

Continue Reading

WednesdaySep 04, 2024 12:55 pm

NetworkNewsBreaks – Trillion Energy International Inc. (CSE: TCF) (OTCQB: TRLEF) Reports Early Return on Investment at SASB Gas Field, Shares August Performance

Trillion Energy (CSE: TCF) (OTCQB: TRLEF), a company focused on oil and natural gas production for Europe and Türkiye with natural gas assets in Türkiye, today provided a production update for the SASB gas field, noting that the SASB revitalization program realized the complete payback of recent perforation costs. According to the update, the Guluc-2, South Akcakoca-2, West Akcakoca-1 and Akcakoca-3 wells started production over a staggered period from July 9 to July 28 and have already produced 140MMcf, representing a 35-day payoff of the recent perforation CAPEX. Gas production from the Akcakoca platform has averaged 4.6 MMcf/d since the…

Continue Reading

WednesdaySep 04, 2024 12:48 pm

NetworkNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Leaders to Present at Upcoming Quantum World Congress 2024

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the world’s first commercial supplier of quantum computers, will participate in this month’s Quantum World Congress. The three-day event is slated for Sept. 9-11, 2024, in Tysons, Virginia. Allison Schwartz, D-Wave’s global government relations and public affairs leader, will contribute to a dynamic workshop, titled “Quantum & Sustainability,” which is scheduled to begin at 12:45 p.m. on Sept. 9. D-Wave senior scientist Dr. Andrew King will participate in a panel titled “Country Showcase: The Canadian Ecosystem,” at 12:30 p.m. on Sept. 10; and Dr. King…

Continue Reading

WednesdaySep 04, 2024 11:40 am

NetworkNewsBreaks – Telomir Pharmaceuticals Inc. (NASDAQ: TELO) Appoints Pharmaceutical Innovation Veteran as Chief Scientific Advisor

Telomir Pharmaceuticals (NASDAQ: TELO), a pre-clinical-stage company seeking to lead developments in longevity science through the treatment of age-related conditions, today announced the appointment of Dr. Itzchak Angel as Chief Scientific Advisor. Dr. Angel’s extensive career in pharmaceutical innovation spans over 40 years, during which he has been instrumental in the research, development, and regulatory approvals of numerous therapies across various therapeutic areas. Dr. Angel will collaborate with Telomir’s senior management to expedite the pre-clinical and clinical path of Telomir-1, the company’s lead product candidate. According to the announcement, Dr. Angel will concentrate his scientific efforts on unveiling and experimentally…

Continue Reading

WednesdaySep 04, 2024 11:03 am

NetworkNewsBreaks – WiSA Technologies, Inc. (NASDAQ: WISA) Executes Definitive Agreement to Create ‘Larger, More Dynamic Entity’ with Broad Reach

WiSA Technologies (NASDAQ: WISA) today announced the execution of a definitive asset purchase agreement to purchase the Datavault(R) intellectual property and information technology assets of privately held Data Vault Holdings Inc. WiSA will pay $210 million as consideration, consisting of 40 million shares of common stock to be issued at $5 per share plus a $10 million 3-year unsecured promissory note. The transaction is expected to close before December 31, 2024, subject to customary conditions and approvals. The purchase will create a publicly traded data technology and licensing company with an extensive patent portfolio serving multiple industries and government entities…

Continue Reading

WednesdaySep 04, 2024 10:38 am

NetworkNewsBreaks – Eloro Resources Ltd. (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM) Provides Update on Its Iska Iska Silver-Tin Polymetallic Project in Southwestern Bolivia

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, today provided an update on its Iska Iska silver-tin polymetallic project in Potosi Department, southern Bolivia. According to the update, an initial program of 5,700m of diamond drilling in 13 holes in the Santa Barbara starter pit area is planned to better define the vertical and lateral extent of high-grade Ag mineralization. This will be followed by an additional 1,400m in two larger PQ holes for further metallurgical testing in Sn mineralization to…

Continue Reading

TuesdaySep 03, 2024 2:48 pm

NetworkNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Announces Additional Orders from European Governments Totaling $2.6M

SuperCom (NASDAQ: SPCB), a global provider of secured solutions for the e-government, Internet of Things (“IoT”) and cybersecurity sectors, has received new orders valued at $2.6 million from different governments in Europe; the company anticipates fulfilling the orders in the next three months. The company offers PureSecurity Suite, an end-to-end electronic monitoring solution that features state-of-the-art GPS tracking, communication and monitoring technologies, as well as a secure software platform providing real-time tracking and reporting. “We are delighted to continue strengthening our collaboration with European governments,” said SuperCom president and CEO Ordan Trabelsi in the press release. “These repeat orders underscore our customers' confidence…

Continue Reading

TuesdaySep 03, 2024 2:27 pm

NetworkNewsBreaks – FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) Announces Closing of Private Placement Final Tranche

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a leading green ammonia company, has closed on a nonbrokered private placement. In addition, the company has issued 8,925,055 units at $0.055 per unit, with each unit consisting of one common share of the company and one common share purchase warrant exercisable at a price of $0.07 until Aug. 29, 2029. Gross proceeds from the placement total an estimated $490,878. The offering is the final tranche of the placement announced in May. The announcement noted that no finders’ fees or commissions were paid in connection with completion of the offering, and all securities issued in connection…

Continue Reading

TuesdaySep 03, 2024 2:06 pm

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Featured in Latest BioMedWire Podcast Episode

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is spotlighted in the most recent episode of IBN’s BioMedWire Podcast. During the episode, CNS Pharmaceuticals CEO John Climaco talks with podcast host Carmel Fisher to explain what sets CNSP’s Berubicin and new TPI-287 candidate apart from anything else in development for glioblastoma. The BioMedWire Podcast features fast-paced interviews with experts guiding the next wave of pharmaceutical and biotech innovation. “We are an oncology drug-development company,” said CNS Pharmaceuticals CEO John Climaco during the…

Continue Reading